The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
In this open study, the therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, was tested in 20 patients with Parkinson's disease who developed levodopa-induced motor response complications. Moclobemide as adjunct therapy reduced "off" time duration for 27%, without an overall motor and functional improvement during their "on" periods. Since it was well tolerated, moclobemide may be specially indicated in elderly or depressed fluctuating parkinsonian patients.
Sternic
N
N
Institute for Neurology CCS, Belgrade, Yugoslavia.
Kacar
A
A
Filipovic
S
S
Svetel
M
M
Kostic
V S
VS
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D004794:Enzyme Repression; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D020912:Moclobemide; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology
D000978:Antiparkinson Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa; D008995:Monoamine Oxidase; D020912:Moclobemide